Janusz Prokopczuk

Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial

Pascal Vranckx, Marco Valgimigli, Peter Jüni et al. · The Lancet · 2018 · 785 citations · Full text

Medicine, Cardiology, Pharmacotherapy +16

Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial

Deepak L. Bhatt, Philippe Gabríel Steg, Shamir R Mehta et al. · The Lancet · 2019 · 210 citations · Full text

Medicine, Cardiology, Pharmacotherapy +15

Ticagrelor Alone Versus Dual Antiplatelet Therapy From 1 Month After Drug-Eluting Coronary Stenting

Anna Franzone, Eugène McFadden, Sergio Leonardi et al. · Journal of the American College of Cardiology · 2019 · 148 citations · Full text

Medicine, Cardiology, Pharmacology +11

Safety and efficacy of a sirolimus-eluting coronary stent with ultra-thin strut for treatment of atherosclerotic lesions (TALENT): a prospective multicentre randomised controlled trial

Azfar Zaman, Robbert J. de Winter, Norihiro Kogame et al. · The Lancet · 2019 · 95 citations

Medicine, Cardiology, Clinical Cardiology +15

Vericiguat in patients with chronic heart failure and reduced ejection fraction (VICTOR): a double-blind, placebo-controlled, randomised, phase 3 trial

Javed Butler, Ciaran J. McMullan, Kevin J. Anstrom et al. · The Lancet · 2025 · 64 citations · Full text

Medicine, Cardiology, Internal Medicine +12